STATEMENT ON THE SUPREME COURT’S DECISION IN FDA V. ALLIANCE FOR HIPPOCRATIC MEDICINE

(WASHINGTON, D.C.) — Today, the Supreme Court issued its decision in FDA v. Alliance for Hippocratic Medicine (AHM), a case in which the plaintiffs sought to severely restrict access to mifepristone, one part of a common two drug medication abortion regimen. In a unanimous decision, the Court ruled that the AHM did not have standing in this case. As a result, mifepristone remains available for now. However, other challenges to medication abortion access are expected.

Power to Decide CEO, Raegan McDonald-Mosley, MD, MPH, issued the following statement in response to the Court’s ruling:

"As a practicing OB-GYN who includes abortion care as part of my practice, I’ve known from the beginning that this case was completely unfounded and not based on science and medicine, but also that this was merely another attempt by anti-abortion activists to further restrict access to mifepristone and abortion care at large.

“Since its FDA approval over 20 years ago, mifepristone has been a safe and effective medication used in conjunction with misoprostol to end pregnancies and manage pregnancy losses. As a health care provider, the most important thing I want people to know is that mifepristone remains safe, effective and available. While we are relieved by the decision of the Court, we know that there is still much work to be done to ensure that everyone who needs it has access to medication abortion and abortion care overall.

“I encourage those needing care to go to AbortionFinder.org where they can get up to date information on the availability of abortion care in their community and where they can access the care and resources they need.”

####
Power to Decide is a nonprofit, nonpartisan organization that works to advance sexual and reproductive well-being for all by providing trusted information, expanding access to quality services, and catalyzing culture change.